MASE
DEAD

Serial Number

85583430

Owner

Molecular Health GmbH

Attorney

Nicole E. Gage

Filing Date

Mar 29, 2012

Add to watchlist:

No watchlists yet
View on USPTO

MASE Trademark

Serial Number: 85583430 • Registration: 4861676

MASE is a trademark filed by Molecular Health GmbH on March 29, 2012. The trademark is classified under Class 42 (Computer & Scientific), Class 44 (Medical Services), Class 35 (Advertising & Business). The application is currently no longer active.

Owner Contact Info

Molecular Health GmbH (44 trademarks)

Belfortstr. 2
Heidelberg 69115 , DE

Entity Type: 03

Molecular Health AG (6 trademarks)

Dufourstr. 25
4010 Basel , CH

Entity Type: 99

Trademark Details

Filing Date

March 29, 2012

Registration Date

December 1, 2015

Published for Opposition

January 21, 2014

Cancellation Date

June 17, 2022

Goods & Services

Data and text processing services, namely, the processing of patient specific information, molecular test results and clinical studies data via computer; data collection services for business purposes, namely, the collection and systematic sorting of clinical and patient data, comprising patient specific molecular and/or genomic data, patient specific clinical data and scientific clinical studies; data collection services for business purposes, namely, the collection of mathematic and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to drug treatments

Providing an online database featuring diagnostic and therapeutic medical, pharmaceutical and genomic information; providing pharmaceutical information, namely, information about drug safety and drug compatibility in relation to the treatment of individual patients; medical and pharmaceutical consulting services in relation to patient medical treatment options and treatment protocols

Data collection for research purposes, namely, the collection and systematic sorting of clinical and patient data, comprising patient specific molecular and/or genomic data, patient specific clinical data and scientific clinical studies; data collection for research purposes, namely, the collection of mathematic and statistical data, clinical data, patient data and data of clinical studies relating to clinical response to drug treatments; compiling data for research purposes in the field of medical science, namely, compiling patient specific molecular and genomic data, patient specific clinical data and scientific clinical studies; providing medical and scientific research in the fields of pharmaceutical side effects genomics, biological medicine and translational medicine; providing an online database comprised of medical, pharmaceutical, biological and genomic information for scientific research purposes; providing an online searchable database in the fields of medical, pharmaceutical, biological, clinical and genomic information for scientific research purposes; providing an online searchable database in the fields of biological medical, translational medicine, interventional epidemiology, bioinformatics, genomic data and genomic sequence analysis for scientific research purposes; providing online non-downloadable computer software for use by healthcare professionals for medical diagnostic and treatment research; software as a service (SAAS) services featuring software for providing information for patient treatment by enabling the retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical purposes; providing online non-downloadable software for retrieval and correlation of genomic data, drug protocols, clinical profiling and integration and statistical analysis of data for medical research purposes; design and development of computer software in the fields of biology, medicine and bioinformatics; design and development of computer software for the integration of patient specific data, molecular test results, clinical studies and scientific results; medical and scientific research and scientific consulting services, namely, designing and conducting drug safety and dosage assessment and drug compatibility studies in the field of cancer therapy for others

Filing History

CANCELLED SEC. 8 (6-YR)
Jun 17, 2022 C8..
COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED
Dec 1, 2020 REM1
REGISTERED-PRINCIPAL REGISTER
Dec 1, 2015 R.PR
1(B) BASIS DELETED; PROCEED TO REGISTRATION
Oct 28, 2015 DP1B
ASSIGNED TO EXAMINER
Oct 19, 2015 DOCK
NOTICE OF ALLOWANCE CANCELLED
Sep 18, 2015 IUCN
TEAS DELETE 1(B) BASIS RECEIVED
Sep 18, 2015 D1BR
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sep 18, 2015 CHAN
TEAS CHANGE OF OWNER ADDRESS RECEIVED
Sep 18, 2015 COAR
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Apr 23, 2015 EXRA
SOU EXTENSION 2 GRANTED
Apr 22, 2015 EX2G
CASE ASSIGNED TO INTENT TO USE PARALEGAL
Apr 22, 2015 AITU
SOU EXTENSION 2 FILED
Mar 18, 2015 EXT2
SOU TEAS EXTENSION RECEIVED
Mar 18, 2015 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Sep 19, 2014 EXRA
SOU EXTENSION 1 GRANTED
Sep 17, 2014 EX1G
SOU EXTENSION 1 FILED
Sep 17, 2014 EXT1
SOU TEAS EXTENSION RECEIVED
Sep 17, 2014 EEXT
AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Aug 20, 2014 ASGN
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Mar 18, 2014 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 21, 2014 NPUB
PUBLISHED FOR OPPOSITION
Jan 21, 2014 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jan 1, 2014 NONP
LAW OFFICE PUBLICATION REVIEW COMPLETED
Dec 17, 2013 PREV
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 13, 2013 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 13, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 13, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 13, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 13, 2013 CNEA
NOTIFICATION OF PRIORITY ACTION E-MAILED
Oct 31, 2013 GPRN
PRIORITY ACTION E-MAILED
Oct 31, 2013 GPRA
PRIORITY ACTION WRITTEN
Oct 31, 2013 CPRA
DATA MODIFICATION COMPLETED
Oct 30, 2013 DMCC
TEAS/EMAIL CORRESPONDENCE ENTERED
Oct 2, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Oct 1, 2013 CRFA
TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Oct 1, 2013 ERSI
SUSPENSION CHECKED - TO ATTORNEY FOR ACTION
Sep 26, 2013 RCCK
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Sep 24, 2013 TCCA
NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Mar 12, 2013 GNS3
LETTER OF SUSPENSION E-MAILED
Mar 12, 2013 GNSL
SUSPENSION LETTER WRITTEN
Mar 12, 2013 CNSL
EXAMINER'S AMENDMENT ENTERED
Mar 11, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 11, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 11, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 11, 2013 CNEA
EXAMINER'S AMENDMENT ENTERED
Mar 5, 2013 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Mar 5, 2013 GNEN
EXAMINERS AMENDMENT E-MAILED
Mar 5, 2013 GNEA
EXAMINERS AMENDMENT -WRITTEN
Mar 5, 2013 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Jan 30, 2013 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Jan 30, 2013 CRFA
ASSIGNED TO LIE
Jan 22, 2013 ALIE
ASSIGNED TO LIE
Jan 22, 2013 ALIE
TEAS CHANGE OF CORRESPONDENCE RECEIVED
Jan 18, 2013 TCCA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Jan 18, 2013 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
Jul 20, 2012 GNRN
NON-FINAL ACTION E-MAILED
Jul 20, 2012 GNRT
NON-FINAL ACTION WRITTEN
Jul 20, 2012 CNRT
ASSIGNED TO EXAMINER
Jul 10, 2012 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Apr 4, 2012 NWOS
NEW APPLICATION ENTERED
Apr 2, 2012 NWAP